Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

The New England Journal of Medicine
Joseph L WitztumEric Bruckert

Abstract

Familial chylomicronemia syndrome is a rare genetic disorder that is caused by loss of lipoprotein lipase activity and characterized by chylomicronemia and recurrent episodes of pancreatitis. There are no effective therapies. In an open-label study of three patients with this syndrome, antisense-mediated inhibition of hepatic APOC3 mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels. We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or placebo. The primary end point was the percentage change in fasting triglyceride levels from baseline to 3 months. Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 3 months, whereas patients receiving placebo had an increase in mean plasma apolipoprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyceride levels, corresponding to a me...Continue Reading

References

Jun 27, 2008·Pancreas·Célia Lloret LinaresEric Bruckert
Nov 3, 2010·Journal of Lipid Research·Christopher T JohansenRobert A Hegele
Jan 14, 2012·Journal of Internal Medicine·R P SurendranG M Dallinga-Thie
Aug 18, 2012·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Björn LindkvistJonas Manjer
Sep 11, 2012·The Journal of Clinical Endocrinology and Metabolism·Lars BerglundUNKNOWN Endocrine society
Sep 27, 2012·Journal of Clinical Lipidology·W Virgil BrownNeil J Stone
Oct 27, 2012·Gut·Peter A BanksUNKNOWN Acute Pancreatitis Classification Working Group
Mar 12, 2013·Genes & Development·Stephen G Young, Rudolf Zechner
May 25, 2013·Circulation Research·Murray W Huff, Robert A Hegele
Nov 1, 2013·Journal of Clinical Gastroenterology·John SchererDhiraj Yadav
Jan 5, 2014·The American Journal of Medicine·Jennifer B ChristianRalph I Horwitz
Oct 2, 2014·European Journal of Internal Medicine·Pedro ValdivielsoNils Ewald
Dec 4, 2014·The New England Journal of Medicine·Daniel GaudetJoseph L Witztum
Mar 4, 2015·Nature Reviews. Endocrinology·Amanda J Brahm, Robert A Hegele
Jul 30, 2015·The New England Journal of Medicine·Daniel GaudetJohn J P Kastelein
Dec 25, 2015·Journal of Clinical Lipidology·Terry A JacobsonUNKNOWN NLA Expert Panel
Jul 12, 2016·The Journal of Clinical Investigation·Philip L S M GordtsJeffrey D Esko
Nov 5, 2016·The Journal of Clinical Endocrinology and Metabolism·Shilpa ShettyAbhimanyu Garg
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Nov 8, 2016·JAMA Internal Medicine·Simon B PedersenBørge G Nordestgaard
Dec 22, 2016·Atherosclerosis. Supplements·Erik StroesMaurizio Averna
Apr 13, 2017·The New England Journal of Medicine·Anne P BeigneuxStephen G Young
Feb 18, 2018·Journal of Clinical Lipidology·William Virgil BrownRob Hegele
Mar 15, 2018·Journal of Clinical Lipidology·William Virgil BrownDaniel Gaudet
May 12, 2018·Journal of Clinical Lipidology·Robert A HegeleDaniel Gaudet
May 23, 2018·Journal of Clinical Lipidology·Michael DavidsonJoseph L Witztum
Oct 16, 2018·Journal of Clinical Lipidology·Dirk J BlomJoseph L Witztum

❮ Previous
Next ❯

Citations

Nov 14, 2019·European Journal of Preventive Cardiology·Vincent A PallazolaSeth S Martin
Nov 26, 2019·European Heart Journal·Ulrich LaufsRobert A Hegele
Nov 23, 2019·Expert Opinion on Investigational Drugs·David RhaindsJean-Claude Tardif
Jan 3, 2020·Current Opinion in Nephrology and Hypertension·Liwei RenA H Jan Danser
Apr 26, 2020·Current Opinion in Lipidology·Debapriya Basu, Ira J Goldberg
Apr 1, 2020·Expert Opinion on Drug Metabolism & Toxicology·Brian TomlinsonChristopher Wai Kei Lam
May 28, 2020·Current Atherosclerosis Reports·Federica FogacciArrigo F G Cicero
Jun 9, 2020·Expert Review of Cardiovascular Therapy·N S NurmohamedE S G Stroes
Jun 11, 2020·Current Opinion in Lipidology·Om P Ganda
May 14, 2020·Cardiovascular Research·Alberico Luigi CatapanoGiuseppe Danilo Norata
Aug 11, 2020·Current Opinion in Lipidology·Godfrey S Getz, Catherine A Reardon
May 7, 2020·Pediatric Hematology and Oncology·Christina MayerhoferChristian Flotho
Aug 28, 2019·Journal of Internal Medicine·Mats Eriksson, Bo Angelin
Dec 28, 2019·The New England Journal of Medicine·Joseph L WitztumLouis O'Dea
Nov 19, 2019·Expert Opinion on Pharmacotherapy·Matilda FlorentinGeorge Liamis
Jul 2, 2020·Journal of Clinical Medicine·Karishma DhuriRaman Bahal
Jun 11, 2020·Cardiovascular Drugs and Therapy·Cinzia Parolini
Jun 5, 2020·Current Atherosclerosis Reports·Aliza HussainSalim S Virani
Feb 26, 2020·Current Opinion in Cardiology·Hapizah Md NawawiGerald F Watts
May 1, 2020·Expert Opinion on Investigational Drugs·Tycho R TrompG Kees Hovingh
Sep 29, 2020·Frontiers in Endocrinology·Leinys S Santos-Baez, Henry N Ginsberg
Aug 11, 2020·Expert Opinion on Pharmacotherapy·Brian TomlinsonChristopher Wai Kei Lam
Aug 8, 2020·Arteriosclerosis, Thrombosis, and Vascular Biology·Haizhao YanJianglin Fan
Feb 20, 2020·Current Opinion in Endocrinology, Diabetes, and Obesity·Antonio J Vallejo-VazKausik K Ray
May 5, 2020·Expert Opinion on Investigational Drugs·Manasvi GuptaRaktim K Ghosh
Apr 14, 2020·The Application of Clinical Genetics·Gabriel D Pinilla-MonsalveJosé A Nastasi-Catanese
May 13, 2020·Der Internist·K G Parhofer
May 23, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Christos BagiasStelios Tigas
Aug 28, 2020·Current Atherosclerosis Reports·Antonio GalloEric Bruckert
Aug 28, 2020·Frontiers in Endocrinology·Debapriya Basu, Karin E Bornfeldt
May 1, 2020·European Heart Journal·Ulf LandmesserThomas F Lüscher
Dec 28, 2019·The New England Journal of Medicine·Sumeet A KhetarpalAmit V Khera
Oct 8, 2020·Current Opinion in Lipidology·Anna WolskaAlan T Remaley
Nov 13, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Albert Youngwoo JangKwang Kon Koh
Jan 13, 2021·Indian Journal of Pediatrics·Kshitija Patil, Neerja Gupta
Dec 29, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Juergen Scharner, Isabel Aznarez
Aug 27, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·C MacchiM Ruscica
Jan 20, 2021·Deutsche medizinische Wochenschrift·Anja Vogt, Oliver Weingärtner
Nov 21, 2020·Annual Review of Medicine·Aliza Hussain, Christie M Ballantyne
Nov 26, 2020·Annual Review of Medicine·Kiran Musunuru
Nov 23, 2020·The Journal of Clinical Endocrinology and Metabolism·Manon BelhassenPhilippe Moulin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Marc S SabatineFOURIER Steering Committee and Investigators
The New England Journal of Medicine
Daniel GaudetJoseph L Witztum
The New England Journal of Medicine
Jennifer G RobinsonODYSSEY LONG TERM Investigators
The New England Journal of Medicine
Gregory G SchwartzODYSSEY OUTCOMES Committees and Investigators
© 2021 Meta ULC. All rights reserved